- Tags: dry eye
Research
Eyelid irrigating retractor achieves ocular lavage for allergic conjunctivitis
Case study supports use of Rinsada in-office for its additive effect in targeting the beginnings of the allergy cascade to help treat the entire ocular surface.
Research
Phase 3b data supports superior tear response with TRYPTYR
Presented at AAO, new findings stem from measuring tear volume produced following administration of the DED drop.
Products
Topcon launches dry eye imager with robotic intelligence
TERA is a multimodal platform for detecting, grading, and managing DED—and pairs robotic automation with high-res imaging for standardized testing.
Research
New data reinforces XIIDRA's eye dryness relief among CL wearers
Open-label study evaluated effectiveness of lifitegrast 5%, noting significant improvements in end-of-day dryness and discomfort in just 2 weeks.
Products
Scope introduces OPTASE HYLO FORTE dry eye drops
Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
Research
TFOS DEWS III report includes use of Lacrifill canalicular gel
Latest installment details two clinical studies validating the use of Nordic Pharma’s FDA-cleared, patented dry eye therapy device.
Research
Cequa's Onset of Action Trial demonstrates rapid ocular surface benefits
Recent data on the FDA-approved, preservative-free eye drop builds on supporting clinical findings—this time for DED patients preparing for refractive-cataract surgery.
Research
24-month data from SAHARA RCT supports TearCare durability for DED
Third set of findings from the long-term study indicates the FDA-cleared system’s ability to deliver “immediate, powerful, repeatable, and long-lasting” dry eye relief.Products
Alcon's TRYPTYR launches to the US market
Company’s first-in-class, prescription-based pharmaceutical features acoltremon, making it the first topical neuromodulator to rapidly increase tear production for DED.
Business
Topcon invests in OKKO Health's home vision monitoring platform
The OKKO Health app is available on patients’ digital devices to enable ongoing self-monitoring of macular degeneration.
Pipeline
FDA accepts Aldeyra's resubmitted reproxalap NDA
Company hopes third submission of the DED application is the charm for achieving marketing approval by a Dec. 26, 2025 PDUFA date.
Research
Bausch + Lomb unveils 2025 state of dry eye survey results
Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Pipeline
Stuart Therapeutics reports initial phase 3 DED eye drop data
Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.
Research
Botox injections may actually help treat DED
Botox injections significantly improved key disease parameters, supporting its potential clinical utility.
Products
CSI Dry Eye Software releases update for AI-based clinical platform
Version 6.0 of the cloud-based software features an intuitive dashboard and automated reminders for clinicians diagnosing and treating DED patients.
Pipeline
Aldeyra resubmits reproxalap NDA for dry eye (again)
Company includes new phase 3 dry eye crossover data in updated submission package; an FDA acknowledgement response is expected within 30 days.
Events
Dry Eye Foundation to host DC advocacy days in July
Nonprofit prepares to kick off its first-ever dry eye patient advocacy day and symposium at the Capitol to raise awareness of the impact of DED on everyday life
Pipeline
FDA clears IND for Zhaoke Ophthalmology's CsA ophthalmic gel
Clearance paves the way for a new phase 3 trial to evaluate CsA 0.05% for its safety and efficacy among moderate-to-severe DED patients—with plans for an eventual NDA submission.
Research
TFOS releases DEWS III Diagnostic Methodology report
Authors of the latest Dry Eye Workshop report call for a simplified patient screening questionnaire, a revised symptomatic DED definition, and updates to risk factors.
Products